Duchenne Muscular Dystrophy (DMD) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32)| Santhera, Sarepta, Italfarmaco, Wave Life Sciences, FibroGen, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor

The Duchenne Muscular Dystrophy market is undergoing a transformative journey, fueled by groundbreaking advancements in medical research and therapeutic innovation. With a heightened focus on precision medicine and gene therapies, pharmaceutical and biotech companies are revolutionizing treatment approaches. This evolving landscape is characterized by increased collaboration among stakeholders, accelerated clinical trials, and a growing array of novel therapies aimed at addressing the complex needs of patients living with Duchenne Muscular Dystrophy.

DelveInsight's "Duchenne Muscular Dystrophy (DMD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Duchenne Muscular Dystrophy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Duchenne Muscular Dystrophy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Duchenne Muscular Dystrophy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Duchenne Muscular Dystrophy (DMD): An Overview
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in children. It is a genetic disorder characterized by progressive muscle degeneration and weakness and is one of nine types of muscular dystrophy.

Duchenne Muscular Dystrophy is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3-5. The disease primarily affects boys, but in rare cases, it can affect girls. Duchenne Muscular Dystrophy is inherited in an X-linked pattern because the gene that can carry a Duchenne Muscular Dystrophy-causing mutation is on the X chromosome. It is caused by mutations of the Duchenne Muscular Dystrophy gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications.

Supportive and symptomatic measures are the basis of the treatment of Duchenne Muscular Dystrophy patients at every stage of the disease and include non-drug, drug, and surgical procedures. Glucocorticoids have long been established as the standard in the therapy of Duchenne Muscular Dystrophy.

The current US market possesses approved products, EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen), in patients with DMD. In the EU4 and the UK, the current market is dominated by steroid therapies along with an approved medication targeting DMD patients with the nonsense mutation, TRANSLARNA (ataluren). In Japan, the only approved treatment is VILTEPSO (viltolarsen).

Get a Detailed Overview of the Evolving Duchenne Muscular Dystrophy Market Trends @
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy (DMD) Market Key Facts
• Duchenne Muscular Dystrophy Market size in the seven major markets was USD 745.4 Million in 2020, which is expected to grow by 2032.
• As per DelveInsight, the Duchenne Muscular Dystrophy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Duchenne Muscular Dystrophy and the launch of new therapies in the market.
• The United States accounts for the largest market size of Duchenne Muscular Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• The United States accounted for the largest market size of Duchenne Muscular Dystrophy USD 623.7 Million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• Among the EU5 countries, the United Kingdom had the largest market size with USD 24.3 Million in 2020, while Spain had the smallest market size of Duchenne Muscular Dystrophy with USD 13.7 Million in 2020.
• Japan accounted for USD 22.7 Million in 2020.
• The total prevalent population of Duchenne Muscular Dystrophy in the 7MM was found to be 30,688 in 2020.
• In the US, approximately 16,765 prevalent cases of Duchenne Muscular Dystrophy were reported in 2020.
• Among the EU-5 countries in 2020, the UK had the highest prevalent population of Duchenne Muscular Dystrophy patients with 2,622 cases, followed by Germany (2,596) and France (2,101). In contrast, Spain had the lowest cases (1,478) in 2020. In the EU5, there were 5,140 and 5,568 cases of ambulatory and non-ambulatory in 2020, respectively.
• In Japan, the diagnosed prevalence of Duchenne Muscular Dystrophy was 3,214 in 2020 which is expected to rise during the forecast period.

Duchenne Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Duchenne Muscular Dystrophy therapies in the market. It also provides a detailed assessment of the Duchenne Muscular Dystrophy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Duchenne Muscular Dystrophy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Duchenne Muscular Dystrophy Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy Epidemiology
The epidemiology section covers detailed insights into the historical, and current Duchenne Muscular Dystrophy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Duchenne Muscular Dystrophy Epidemiology Segmented as -
• Total Prevalent Population of Duchenne Muscular Dystrophy
• Age-specific Prevalent Population of Duchenne Muscular Dystrophy
• Ambulatory and Non-ambulatory Population of Duchenne Muscular Dystrophy
• Mutation-specific prevalent population of Duchenne Muscular Dystrophy
• Associated Comorbidities in Duchenne Muscular Dystrophy

Get Key Insights Into the Evolving Duchenne Muscular Dystrophy Epidemiology Trends @
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the market share by Duchenne Muscular Dystrophy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Duchenne Muscular Dystrophy Market @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy (DMD) Therapeutics Assessment
Although there is no cure for any form of muscular dystrophy, treatment for some forms of the disease including DMD can help extend the time a person with the disease can remain mobile and help with heart and lung muscle strength. The main therapeutic strategies for the treatment of DMD include gene replacement or other genetic therapies linked to specific mutations to restore dystrophin production, membrane stabilization and/or upregulation of compensatory proteins and reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Moreover, several guidelines on the diagnosis and multidisciplinary management of DMD include the use of corticosteroids, which offer benefits to boys with DMD by stabilizing muscle strength and function prolonging independent ambulation, and delaying the progression of scoliosis and cardiomyopathy.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Duchenne Muscular Dystrophy. Currently, Roche is leading the therapeutic market with its Duchenne Muscular Dystrophy drug candidates in the most advanced stage of clinical development.

Leading Companies in the Duchenne Muscular Dystrophy Therapeutics Market Include
Some of the key companies in the Duchenne Muscular Dystrophy Therapeutics include Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and many others.

Emerging and Marketed Duchenne Muscular Dystrophy Therapies Covered in the Report Include
• Amondys 45: Sarepta Therapeutics
• Emflaza: PTC Therapeutics
• Exondys 51: Sarepta Therapeutics
• Givinostat: Italfarmaco
• Pamrevlumab: Fibrogen
• PF-06939926: Pfizer
• Pizuglanstat (TAS-205): Taiho Pharmaceutical
• Translarna: PTC Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
• Viltepso: Nippon Shinyaku
• Vyondys 53 (Golodirsen): Sarepta Therapeutics
And Many More

Learn More About the Emerging Therapies and key Companies in the Duchenne Muscular Dystrophy Therapeutics Market @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis
4. Duchenne Muscular Dystrophy Market Overview at a Glance
5. Duchenne Muscular Dystrophy Background and Overview
6. Duchenne Muscular Dystrophy Patient Journey
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Duchenne Muscular Dystrophy Unmet Needs
10. Key Endpoints of Duchenne Muscular Dystrophy Treatment
11. Duchenne Muscular Dystrophy Marketed Products
12. Duchenne Muscular Dystrophy Emerging Therapies
13. Duchenne Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Duchenne Muscular Dystrophy Market Outlook (7 major markets)
16. Duchenne Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Duchenne Muscular Dystrophy Market.
18. Duchenne Muscular Dystrophy Market Drivers
19. Duchenne Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.